Michael Rogawski
Consultant / Advisor chez XENON PHARMACEUTICALS INC.
Profil
Michael A Rogawski is the founder of Marinus Pharmaceuticals, Inc.,Epalex Corp.
He currently serves as a member of the Scientific Advisory Board for Zogenix, Inc., GW Pharmaceuticals Ltd., and Xenon Pharmaceuticals, Inc. He is also a Venture Partner at Catalio Capital Management LP.
Previously, he served as a member of the Scientific Advisory Board for Aquestive Therapeutics, Inc. and Zynerba Pharmaceuticals, Inc. Dr. Rogawski holds a doctorate degree from Yale University.
Postes actifs de Michael Rogawski
| Sociétés | Poste | Début |
|---|---|---|
| XENON PHARMACEUTICALS INC. | Consultant / Advisor | - |
| GW PHARMACEUTICALS PLC | Consultant / Advisor | - |
| ZOGENIX, INC. | Consultant / Advisor | - |
Catalio Capital Management LP
 Catalio Capital Management LP Investment ManagersFinance Catalio Capital Management LP (Catalio Capital) is a venture capital firm founded in 2020 by George Petrocheilos and Dr. Jacob Vogelstein. The firm is headquartered in New York. | Consultant / Advisor | - |
Epalex Corp.
 Epalex Corp. Miscellaneous Commercial ServicesCommercial Services Epalex Corp. engages in the development of novel treatments for migraine and epilepsy. The treatment for the first time provides a way for patients with epilepsy to gain control over their seizures. The firm also develops transformational products for seizure prophylaxis in patients suffering from primary generalized epilepsies. The company was founded Randall B. Murphy and is headquartered in Palo Alto, CA. | Fondateur | - |
Anciens postes connus de Michael Rogawski
| Sociétés | Poste | Fin |
|---|---|---|
| ZYNERBA PHARMACEUTICALS, INC. | Consultant / Advisor | 10/10/2023 |
| AQUESTIVE THERAPEUTICS, INC. | Consultant / Advisor | - |
| MARINUS PHARMACEUTICALS, INC. | Fondateur | - |
Formation de Michael Rogawski
| Yale University | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 4 |
|---|---|
| MARINUS PHARMACEUTICALS, INC. | Health Technology |
| XENON PHARMACEUTICALS INC. | Health Technology |
| ZYNERBA PHARMACEUTICALS, INC. | Health Technology |
| AQUESTIVE THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 4 |
|---|---|
Catalio Capital Management LP
Catalio Capital Management LP Investment ManagersFinance Catalio Capital Management LP (Catalio Capital) is a venture capital firm founded in 2020 by George Petrocheilos and Dr. Jacob Vogelstein. The firm is headquartered in New York. | Finance |
GW Pharmaceuticals Ltd.
 GW Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology GW Pharmaceuticals Ltd. operates as an intermediate holding company and management company for investments in its subsidiaries. The company was founded by Geoffrey William Guy and Brian Whittle in 1998 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
Zogenix, Inc.
 Zogenix, Inc. Pharmaceuticals: MajorHealth Technology Zogenix, Inc. is a pharmaceutical company. The firm engages in the development and commercialization of central nervous system (CNS) therapies and products for the treatment orphan diseases and other CNS disorders. Its products include Fintepla and MT1621. The company was founded by Stephen James Farr, Cam L. Garner, Roger L. Hawley, Bret E. Megargel, Jonathan M. N. Rigby, Scott L. Glenn, and John J. Turanin on May 11, 2006 and is headquartered in Emeryville, CA. | Health Technology |
Epalex Corp.
Epalex Corp. Miscellaneous Commercial ServicesCommercial Services Epalex Corp. engages in the development of novel treatments for migraine and epilepsy. The treatment for the first time provides a way for patients with epilepsy to gain control over their seizures. The firm also develops transformational products for seizure prophylaxis in patients suffering from primary generalized epilepsies. The company was founded Randall B. Murphy and is headquartered in Palo Alto, CA. | Commercial Services |